What is the current size and annual growth rate of the multiplex biomarker imaging market?
The multiplex biomarker imaging market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to the high incidence of cancer, the need for precise diagnostic tools, the growing prevalence of chronic diseases, the increase in the aging population, and the shift towards personalized medicine.
The multiplex biomarker imaging market size is expected to see rapid growth in the next few years. It will grow to $0.82 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing emphasis on personalized medicine, increased research and development activities, increasing clinical trials, the need for high throughput screening methods in drug discovery, and supportive regulatory frameworks and guidelines. Major trends in the forecast period include technological advancements, innovations in imaging technologies, advances in digital pathology, developments in data analysis and imaging software, and integration of AI and machine learning with imaging technologies.
Get Your Free Sample of The Global Multiplex Biomarker Imaging Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16127&type=smp
How has the multiplex biomarker imaging market evolved, and what factors have shaped its growth?
The rising prevalence of chronic diseases is expected to propel the growth of the multiplex biomarker imaging market going forward. Chronic diseases are long-lasting health conditions that persist or recur over time, often with complex causes, multiple risk factors, and long latency periods. The growing prevalence of chronic diseases is attributed to several factors, including the rapid aging of the population, improved case finding and detection, better treatment and management of diseases, and changes in lifestyle and environmental risk factors. Multiplex biomarker imaging is utilized in chronic disease management for comprehensive analysis and characterization of disease progression and treatment response. For instance, in January 2023, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the multiplex biomarker imaging market.
What are the major segments of the multiplex biomarker imaging market?
The multiplex biomarker imaging market covered in this report is segmented –
1) By Component Type: Instruments, Software, Services
2) By Imaging Techniques: Immuno Fluorescence (IF) Assay, Tissue Microarray (TMA) Assay, Immunohistochemistry (IHC) Assay, Fluorescent In The Situ Hybridization (FISH) Assay, Toponome Imaging System (TIS)
3) By Application: Drug Safety, Oncology Studies, Genetic Characterization Studies
4) By End User: Research Institutes Government And Private, Clinical Labs, Pharmaceutical And Biotechnology
Subsegments:
1) By Instruments: Imaging Systems (Microscopes, Scanners), Detection Devices (Sensors, Probes), Reagents And Kits
2) By Software: Image Analysis Software, Data Management Software, Visualization And Interpretation Software
3) By Services: Technical Support And Maintenance, Consultation And Training, Imaging And Analysis Services
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/multiplex-biomarker-imaging-global-market-report
Which companies dominate the multiplex biomarker imaging market?
Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies
How will evolving trends contribute to the growth of the multiplex biomarker imaging market?
Major companies operating in the multiplex biomarker imaging market are focusing on providing innovative slides, such as automated slide loaders, to provide advanced imaging solutions and better serve customers. Automated slide loaders streamline sample handling, reducing hands-on time and enhancing throughput, which is crucial for high-volume multiplex biomarker imaging experiments. For instance, in April 2024, Standard BioTools Inc., a US-based provider of analytical systems and instruments, launched a Hyperion XTi Imaging System with a new high-throughput multiplexed whole slide to add automation and flexibility. It has three modes for rapid analysis, including preview, tissue, and cell modes. Researchers can visualize tissue heterogeneity quickly and conduct deeper analysis. This novel whole slide imaging method using imaging mass cytometry (IMC) offers up to 10 times higher throughput than cyclic immunofluorescent imaging. Additionally, a new automated slide loader facilitates high-throughput imaging, reducing hands-on time and enabling standardization. These innovations aimed to accelerate breakthroughs in spatial proteomics, providing reliable insights into health and disease.
What are the key regional dynamics of the multiplex biomarker imaging market, and which region leads in market share?
North America was the largest region in the multiplex biomarker imaging market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Multiplex Biomarker Imaging Market Report 2025 Offer?
The multiplex biomarker imaging market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Multiplex biomarker imaging is a technique that allows for the simultaneous detection and analysis of multiple biomarkers within a single sample, enabling the visualization of complex biological processes and molecular profiles. This method uses advanced imaging technologies to map the spatial distribution of biomarkers within tissues, providing detailed insights into cellular interactions and microenvironments.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16127
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
